ReviewEndocrine reviews2019
The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk.
Review in Endocrine reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 321 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
321 citing papers in PubMed, 3 syntheses or guidelines pooled it, 579 citations in OpenAlex.
- High Remnant Cholesterol Increased the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) or Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis.Journal of the ASEAN Federation of Endocrine Societies · 2026Pooled it
- The effect of Hp infection on dyslipidemia in Asia and out of Asia: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Risk factors for cardiovascular diseases in patients with vitiligo: an analysis of current evidence.Annals of medicine · 2024Pooled it
- Remnant cholesterol level modified the effects of intensive systolic blood pressure lowering treatment in high-risk hypertensive patients: a post hoc analysis of the ESPRIT trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Trial
- Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy.Arteriosclerosis, thrombosis, and vascular biology · 2025Trial
- Association of pre-pregnancy body mass index and first-trimester remnant cholesterol level with risk of large for gestational age.Journal of global health · 2026Article
- SNAI2/SLUG: a key regulator of endothelial-to-mesenchymal transition and vascular remodeling in cardiovascular diseases.Journal of cardiothoracic surgery · 2026Review
- Effects of Ban Lian Zi Jin compound on intestinal barrier and apoptosis of Heat-stressed broilers.Poultry science · 2026Article
- Postprandial Inflammatory Stress: A Hypothesis-Generating Framework Linking Metabolic, Immune and Vascular Responses.Life (Basel, Switzerland) · 2026Review
- Association between remnant cholesterol and short-term hearing outcomes in sudden sensorineural hearing loss.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Impacts of Remnant Cholesterol and Residual Inflammation on Clinical Outcomes After Ischemic Stroke.JACC. Advances · 2026Article
- Discordance between remnant cholesterol and low-density lipoprotein cholesterol predicts incident hypertension: a 9-year prospective cohort study in Chinese adults.BMC cardiovascular disorders · 2026Article
- PCSK9 inhibitors do not increase cognitive risk.Biology direct · 2026Article
- The association of nontraditional lipid parameters with all-cause and cardiovascular mortality: A national cohort study.Medicine · 2026Article
- Hypertriglyceridaemia and its multifaceted mechanisms driving atherosclerotic cardiovascular disease.Lipids in health and disease · 2026Review
- Remnant cholesterol is independently associated with liver fibrosis in metabolic dysfunction-associated fatty liver disease patients and rats.Scientific reports · 2026Article
- An Experiment in Personalized Shopping for Optimal Health, with Integration of Nutrigenetics and Gut Microbiome Information.Nutrients · 2026Article
- Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL clearance and regress atherosclerosis on atorvastatin background.Journal of lipid research · 2026Article
- Association of triglyceride-driven residual atherosclerotic risk with carotid stiffening assessed using ultrafast ultrasound imaging in individuals with hypertriglyceridemia.Ultrasonography (Seoul, Korea) · 2026Article
- Association between remnant cholesterol and colorectal cancer risk in Korea: a nationwide population-based study.The Korean journal of internal medicine · 2026Article
261 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide. Low-density lipoprotein cholesterol (LDL-C) is a well-established mediator of atherosclerosis and a key target for intervention for the primary and secondary prevention of ASCVD. However, despite substantial reduction in LDL-C, patients continue to have recurrent ASCVD events. Hypertriglyceridemia may be an important contributor of this residual risk. Observational and genetic epidemiological data strongly support a causal role of triglycerides (TGs) and the cholesterol content within triglyceride-rich lipoproteins (TGRLs) and/or remnant cholesterol (RC) in the development of ASCVD. TGRLs are composed of hepatically derived very low-density lipoprotein and intestinally derived chylomicrons. RC is the cholesterol content of all TGRLs and plasma TGs serve as a surrogate measure of TGRLs and RC. Although lifestyle modification remains the cornerstone for management of hypertriglyceridemia, many novel drugs are in development and have shown impressive efficacy in lowering TG levels. Several ongoing, randomized controlled trials are underway to examine the impact of these novel agents on ASCVD outcomes. In this comprehensive review, we provide an overview of the biology, epidemiology, and genetics of TGs and ASCVD; we discuss current and novel TG-lowering therapies under development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.